Home > Boards > US Listed > Medical - Drugs >

Arbutus Biopharma Corporation (ABUS)

ABUS RSS Feed
Add ABUS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, DewDiligence
Search This Board: 
Last Post: 5/7/2022 2:08:49 PM - Followers: 130 - Board type: Free - Posts Today: 0



UPDATE; 10-12-2021
$abus uptrend wedge, inverted head & shoulder too.

[-chart]charts.stocktwits.com/production/original_385257980.jpg[/chart]




UPDATE; 10-09-2021
$ABUS COURTESY OF


$ABUS HEARING VIDEO
Twitter Spaces re Moderna v Arbutus Patent Appeal Oral Argument
460 viewsOct 7, 2021
https://www.youtube.com/watch?v=3duSGLOygX0&ab_channel=DanRavicher

UPDATE;
Reviewing 10-06-2021 $ABUS FACTS: & $ABUS WOW FOR INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!

ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS


1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant

AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!

MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE



UPDATE;09-27-2021
ABUS and Roivant launched Genevant as a joint venture in 2018.

Roivant will begin trading as ROIV this Friday, assuming its' merger with the MAAC SPAC is approved Tuesday.

Since Genevant is 60% owned by Roivant and 40% owned by ABUS, it sits under the Roivant banner as one of the Roivant Vants.
There were no shares spun off because Genevant remains private.


From https://www.dcatvci.org/6162-emerging-pharma-roivant-sciences-on-the-rise

"Vivek Ramaswamy is leading a family of companies that include multiple wholly owned or majority-owned subsidiaries (so-called “Vants”),
each focused on a different disease area or technology that supports the process of developing and commercializing medicines.
The company employs a “hub and spoke” model for research and development, whereby each biopharmaceutical subsidiary functions as
an independent entity (“spoke”) using shared resources from the parent (“hub”)
and the technology-based subsidiaries focused on different aspects of data science."



https://www.globenewswire.com/en/news-release/2018/04/11/1468874/14025/en/Arbutus-and-Roivant-Launch-Genevant-Sciences-with-Industry-Leading-Platform-to-Develop-Broad-Range-of-RNA-Therapeutics-for-Genetic-Diseases.html

"Under the terms of the agreement, Roivant will contribute $37.5 million in transaction-related seed capital for Genevant.
Roivant is committed to financially support Genevant in its aim to advance 5 to 10 product candidates into the clinic by 2020.
Arbutus will retain all rights to the LNP and conjugate delivery platforms for HBV,
and will be entitled to a tiered royalty from Genevant on future sales of products enabled by those delivery platforms.
Arbutus will also retain the entirety of its royalty entitlement on the commercialization of Alnylam’s patisiran,
which could see regulatory approval as early as the second half of 2018."



In April 2018, Arbutus and Roivant Sciences Ltd. (its largest shareholder) launched the spinoff Genevant Sciences Ltd. (“Genevant”).
Under the terms of that deal, Arbutus licensed exclusive rights to its non-HBV LNP technology to Genevant (including the ‘069 patent)
and took a minority 40% common equity share in Genevant, compared to Roivant’s 60% share.




'COMPANY ORGANIZATION CHART' 09-26-2021
$ABUS [-chart]charts.stocktwits.com/production/original_383829800.png[/chart]




UPDATE; 09-10-2021
$ABUS HIGHLIGHTS
NO DEBT
Insider Own 19.15%
Inst Own 31.70%
Inst Trans 11.15%
Shs Outstand 96.87M
Shs Float 80.17M
Target Price 5.90 [WITHOUT INFRINGEMENT PATENT
PENDING]
52W Range 2.35 - 5.87
https://finviz.com/quote.ashx?t=ABUS
 
 
UPDATE; 09-10-2021

Arbutus rises 15% on apparent patent fight win with Moderna

Sep. 09, 2021 4:20 PM ETABUS, BNTX...By: Jonathan M BlockSA News Editor
https://seekingalpha.com/news/3738496-arbutus-rises-15-on-apparent-patent-fight-win-with-moderna
  • Shares of Arbutus Biopharma (NASDAQ:ABUS) closed up 15% amid speculation it has won a patent fight against Moderna (NASDAQ:MRNA).
    Arbutus may receive a new patent and as a result, may be eligible for royalties from Moderna from sales of its COVID-19 vaccine.
    The U.S. Patent and Trademark Office website shows that Arbutus was granted a notice of allowance on Sept. 2 for a patent covering novel lipid formulations for nucleic acid delivery.
    In the past, Moderna has unsuccessfully challenged similar patents.
    Moderna is appealing the validity of those patents with a hearing before a federal appellate court on Oct. 7
    An article published in Forbes last month highlighted that scientific papers and regulatory documents indicate that both Moderna's vaccine and
    Pfizer (NYSE:PFE)/BioNTech's (NASDAQ:BNTX) use a delivery system that is quite similar to what Ian McLachlan, who worked at Tekmira, which later changed its name to Arbutus, created.

 



http://www.arbutusbio.com/

http://www.arbutusbio.com/about-arbutus/overview.php
https://investor.arbutusbio.com/scientific-advisory-board
http://www.arbutusbio.com/about-hbv/hbv-science.php
PARTNERS
http://www.arbutusbio.com/portfolio/genevant.php
http://www.arbutusbio.com/partners/partnerships.php
http://www.arbutusbio.com/partners/hbv-partnerships.php
https://investor.arbutusbio.com/press-releases



UPDATE; 04-27-2021
#2 $ABUS FACTS: & $ABUS WOW FOR DIS INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!

ABUS 
1) May 4th Appeals Briefs due in MRNA vs ABUS  069. Oral next. ABUS asked for extension.ABUS 


1) May 4th Appeals Briefs due in MRNA vs ABUS  069. Oral next. ABUS asked for extension.
2) May 5th.  HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020 
4) NO major PR since mid March,  PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020. 
7) Announced 
$75M
Offering last meeting. ATM.  At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.  
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.  
24 million shares at $7.  Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year  "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!!  AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant

AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!

MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses: 
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE







11-17-2020
Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS).

https://www.smarteranalyst.com/new-blurbs/chardan-capital-remains-a-buy-on-arbutus-biopharma-abus/?mod=mw_quote_news

11-17-2020
$ABUS [B.Riley Financial Keeps a Buy Rating on Arbutus Biopharma (ABUS).]

https://www.smarteranalyst.com/new-blurbs/b-riley-financial-keeps-a-buy-rating-on-arbutus-biopharma-abus/?mod=mw_quote_news



$ABUS #2 RATING $8 JMP Securities Initiates Coverage on Arbutus Biopharma (NASDAQ:ABUS)
SHARE
MONDAY, JULY 27, 2020 | MARKETBEAT

https://www.marketbeat.com/instant-alerts/nasdaq-abus-a-buy-or-sell-right-now/


 
Arbutus  T$MRNA &$ABUSGOOD STUFF Sunday, 26 July 2020
Moderna Must Move Quickly To Buy Arbutus
Arbutus Biopharma Corporation (ABUS)
Current Price: $4.96
Target Price: $15.00
Upside Potential: 202%
Market Cap: $342 million
Shares Outstanding: 69 million
Float: 38 million
https://value-trades.blogspot.com/


http://www
http://www.arbutusbio.com/about-arbutus/overview.php
http://www.arbutusbio.com/
http://www.arbutusbio.com/about-hbv/hbv-science.php
http://www.arbutusbio.com/about-hbv/blumberg.php
http://www.arbutusbio.com/portfolio/ab-729-galnac-rnai.php
http://www.arbutusbio.com/portfolio/capsid-inhibitors.php
http://www.arbutusbio.com/portfolio/hbv-rna-destabilizer.php $MRNA &$ABUSGOOD STUFF Sunday, 26 July 2020
 
https://value-trades.blogspot.com/

PARTNER;
http://www.arbutusbio.com/portfolio/genevant.php
http://www.arbutusbio.com/portfolio/gritstone.php
http://www.arbutusbio.com/portfolio/patrisiran.php
http://www.arbutusbio.com/portfolio/marqibo.php

PARTERS;
http://www.arbutusbio.com/partners/hbv-partnerships.php
http://www.arbutusbio.com/partners/partnering-licensing-opportunities.php


 
All Navigate to...- Any - Releases
May 27,2020
 
May 18,2020
 
May 12,2020
 
May 11,2020
 
May 04,2020
 
Mar 26,2020
 
Mar 05,2020
 
Feb 27,2020
 
Feb 10,2020
 
Nov 06,2019

[-chart]finviz.com/chart.ashx?t=ABUS&ty=c&ta=1&p=d&s=l[/chart]




https://finviz.com/quote.ashx?t=ABUS&ty=c&ta=1&p=d   [SHARES HAVE INCREASED SOME SINCE DIS WAS DONE 04-27-2021]
Shs Outstand 67.68M
Shs Float 44.46M
 
Short Float 1.72%
Debt/Eq   NO DEBT -
 
Inst Own 38.60%
 
Cash/sh 0.98
Sales Q/Q 114.30%
EPS Q/Q 46.60%
52W Range 0.82 - 6.48


$ABUS FIVE YR.





https://www.otcmarkets.com/stock/ABUS/disclosure

https://www.otcmarkets.com/stock/ABUS/news

https://www.otcmarkets.com/stock/ABUS/security

https://www.otcmarkets.com/stock/ABUS/profile

https://www.otcmarkets.com/stock/ABUS/quote

https://www.otcmarkets.com/stock/ABUS/overview








 

PER  IHUB  MGMT 

02-07-2021
DISCLAIMER:  ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
 
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION 
AUTHORS MAY HAVE BUYS OR SELLS  WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.

ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Any



 







 
ABUS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ABUS News: Arbutus to Present at H.C. Wainwright Global Investment Conference 05/17/2022 03:30:00 AM
ABUS News: Morning Brief: Top Financial Stories Dominating on Monday, May 9 05/09/2022 04:29:31 AM
ABUS News: Quarterly Report (10-q) 05/05/2022 12:22:46 PM
ABUS News: JMP Securities Thinks Arbutus Biopharma’s Stock is Going to Recover 05/05/2022 11:05:11 AM
ABUS News: Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update 05/05/2022 03:30:00 AM
PostSubject
#6603  Sticky Note MRNA seeks_dismissal of ABUS patent-infringement suit on_legal_technicality: DewDiligence 05/07/22 02:08:49 PM
#6580  Sticky Note MRNA PFE BNTX COURT FILING WON BY ABUS mick 01/02/22 01:14:57 PM
#6603   MRNA seeks_dismissal of ABUS patent-infringement suit on_legal_technicality: DewDiligence 05/07/22 02:08:49 PM
#6602   ABUS 1Q22 CC transcript: DewDiligence 05/05/22 04:00:32 PM
#6601   ABUS cash @3/31/22=$222M, up $31M from 12/31/21 due DewDiligence 05/05/22 11:29:19 AM
#6600   Arbutus Biopharma Co (ABUS) mick 05/01/22 03:28:20 PM
#6599   March 18, 2022 02:29 PM ET (BZ Newswire) Paullee 03/18/22 03:26:32 PM
#6598   Arbutus Biopharma Co (ABUS) mick 03/12/22 03:21:35 PM
#6597   ROIV owns a 37% stake in ABUS, according DewDiligence 03/03/22 10:57:31 AM
#6596   The ABUS-Antios HBV trial_has_been_truncated_by_ war_in Ukraine; from ABUS’ DewDiligence 03/03/22 10:56:16 AM
#6595   ABUS 4Q21 financials: DewDiligence 03/03/22 10:55:49 AM
#6594   My viewpoint in #msg-166969942 still pertains. DewDiligence 02/28/22 10:11:35 AM
#6593   why take so long filing ????? corporate mick 02/28/22 09:42:15 AM
#6592   On February 28, 2022, Arbutus Biopharma Corporation (the Slojab 02/28/22 09:36:34 AM
#6591   Arbutus Biopharma Co (ABUS) mick 02/06/22 05:44:31 PM
#6590   Why shouldn't it have been? Slojab 02/04/22 10:48:50 AM
#6589   Then why is it down zephyroo 02/04/22 02:06:31 AM
#6588   WEDNESDAY, FEBRUARY 2, 2022 / MARKETBEAT Arbutus Biopharma Slojab 02/02/22 11:02:41 AM
#6587   Which 8-K filing are you referring to? DewDiligence 01/29/22 11:24:26 AM
#6586   In the 8K they said the investor bought PavanTheWay 01/29/22 11:18:53 AM
#6585   CASH-COW $ABUS Current Report Filing (8-k) mick 01/24/22 10:08:15 AM
#6584   $ABUS cash-cow 01-24-2022 Financial position significantly strengthened; cash mick 01/24/22 10:03:31 AM
#6583   i like da read --- #2 $ABUS Multiple mick 01/24/22 10:01:54 AM
#6582   Arbutus Announces 2022 Corporate Objectives and Provides Financial Update mick 01/24/22 09:54:23 AM
#6581   https://www.otcmarkets.com/stock/ABUS mick 01/02/22 07:15:00 PM
#6580   MRNA PFE BNTX COURT FILING WON BY ABUS mick 01/02/22 01:14:57 PM
#6579   CHECK OUT THE SEEKING ALPHA ARTICLE ON STOCKTWITS love to be rite once 12/22/21 12:12:21 AM
#6578   A follow up report to the news from Monday. Slojab 12/17/21 06:40:01 PM
#6577   Nice, let’s close strong! Little Run 12/17/21 03:06:07 PM
#6576   Institutional Holdings Slojab 12/17/21 10:42:41 AM
#6575   NEW 8K OUT love to be rite once 12/14/21 08:19:02 AM
#6574   Added @$4.18 today. First buy was @$4.75 last Little Run 12/13/21 05:18:56 PM
#6573   ABUS inks Greater-China* development deal for AB-729—$40M up-front cash: DewDiligence 12/13/21 11:23:20 AM
#6572   $ABUS courtesy of Howdy partners!! The markets delivered mick 12/12/21 12:21:18 PM
#6571   I CAN SEE $5.00 MONDA 12-13-2021 mick 12/11/21 07:55:37 PM
#6570   mick went there do not see anything. love to be rite once 12/11/21 07:52:00 PM
#6569   https://www.otcmarkets.com/stock/ABUS TO JUMP 100% ????? mick 12/11/21 07:28:06 PM
#6568   Goes over $5 today Oger 12/10/21 09:42:50 AM
#6567   I DO NOT UNDERSTAND EITHER, WHY. SOME NO mick 12/09/21 07:42:16 PM
#6566   It’s SUPER active on Stocktwits 1maga1 12/09/21 06:20:32 PM
#6565   Why is this board so quiet?? most Splendid88 12/09/21 05:57:14 PM
#6564   $ABUS Arbutus identifies molecular targets for COVID-19 treatment mick 12/07/21 04:58:37 PM
#6563   SECRETS/HANDLING WIT WHITE GLOVE TREATMENT Arbutus Biopharma Corporation (ABUS)' mick 12/07/21 04:57:32 PM
#6562   Thanks for your input mick. Seems to Splendid88 12/07/21 03:08:50 PM
#6561   it is my friend mmm boys shorting Arbutus mick 12/07/21 02:54:39 PM
#6560   dats my price area too or much higher mick 12/07/21 02:29:47 PM
#6559   Reviewing 12-08-2021 $ABUS/ GenevantFACTS: & $ABUS WOW FOR mick 12/07/21 02:28:47 PM
#6558   $ABUS Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It mick 12/07/21 02:24:23 PM
#6557   On the move! KeepOn 12/06/21 11:24:49 PM
#6556   Think about it. If moderna just buys Splendid88 12/06/21 12:18:25 PM
#6555   I can't seem to find any new info Splendid88 12/06/21 12:15:51 PM
#6554   $abus new patent lnp mick 12/05/21 04:29:41 PM
PostSubject
Consent Preferences